Browsing Tag
3SBio
2 posts
How 3SBio became China’s most watched biotech firm after the Pfizer deal
3SBio is now at the center of global oncology focus after licensing SSGJ-707 to Pfizer. Explore what’s driving its stock surge and strategic ascent.
Pfizer’s $6.05bn bet on oncology innovation: Inside the 3SBio SSGJ-707 licensing deal
Find out how Pfizer’s $6.05B deal with 3SBio could reshape the global cancer immunotherapy market with PD-1/VEGF bispecific SSGJ-707.